Background Resting vascular tone is low in the normal pulmonary circulation, and experimental studies have suggested that this may be due to the continuous release of endothelium-derived nitric oxide (NO), a locally acting vasodilator. We have investigated whether NO contributes to the normal control of pulmonary vascular tone and resistance in children.
T he vascular endothelium produces a labile substance, endothelium-derived relaxing factor (EDRF), that mediates the vasodilator effects of certain pharmacological agents (such as acetylcholine and substance P).1 There is increasing evidence from experimental studies that continuous release of EDRF is important in maintaining low pulmonary vascular tone. [2] [3] [4] In lambs, infusing a specific antagonist of EDRF produces pulmonary hypertension. 5 EDRF is now known to be nitric oxide (NO),6 which is synthesized from the amino acid L-arginine or a closely related compound. Arginine analogues, such as N0-monomethyl-L-arginine (L-NMMA), cause specific inhibition of NO formation in vascular endothelial cells7 and inhibit endothelium-dependent relaxation. Vallance et a18 demonstrated that L-NMMA causes a fall in basal forearm blood flow and therefore suggested that NO is constantly secreted by systemic vascular endothelial cells. Since endothelial dysfunction may be an important early event in pulmonary vascular disease complicating certain congenital heart lesions, we used intrapulmonary infusions of L-NMMA and L-arginine to assess whether intact pulmonary endothelium maintains low vascular tone in the lungs of children with normal pulmonary hemodynamics.
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Methods Patients
We studied six children (three boys and three girls) 2 to 17 years old (mean, 9±2 years) who were undergoing cardiac catheterization as part of the routine clinical evaluation of congenital heart disease. We were unable to study children without heart disease, who do not usually undergo catheterization, but selected subjects with normal pulmonary hemodynamics. All had isolated left heart obstructive lesions (aortic valve stenosis in three, subaortic stenosis in two, and recoarctation of the aorta in one). None had had previous bypass surgery, parenchymal lung disease, or any chromosomal or extracardiac abnormalities, and none were taking medications. Balloon dilatations were performed in four, and two were catheterized for diagnostic purposes only. Informed consent was obtained in all cases, and the study was approved by the local committee on ethical practice.
Study Protocol
After benzodiazepine premedication, all children had cardiac catheterization via the femoral approach under general anesthesia. During all studies, FIo2 was 0.21, general anesthesia was maintained with an intravenous agent (propofol) rather than volatile gas inhalation, and care was taken to avoid anesthesiarelated hypotension. Arterial blood gases were taken at the beginning, during, and at the end of each study to exclude carbon dioxide retention and to document respiratory stability throughout the infusion protocol. At 
Results
Hemodynamic Data All subjects had normal pulmonary hemodynamics; mean pulmonary artery pressure was 15±1 mm Hg, and pulmonary vascular resistance index was 1.1+0.1 U * M2 (Table) . All patients were stable throughout the protocol, including arterial Pco2. The pulmonary and systemic artery pressures and heart rate were monitored continuously, and no parameter changed by 210% during any of the studies.
Experimental Protocol
In every patient, L-NMMA caused a fall in pulmonary flow velocity to 75+±7% (range, 46% to 88%), 62±8% (range, 35% to 81%), and 40±10% (range, 10% to 72%) of the baseline value for the three increasing doses given (P<.01 by ANOVA) (Figure) . The lower dose of L-arginine restored these values to baseline within 3 minutes (106±8% [range, 92% to 122%] compared with control), and there was no further effect from the higher dose. In the three subjects given a 5-minute control infusion between L-NMMA and L-arginine, the flow velocity values remained decreased during the control period (50+14%, P=NS compared with the final infusion of L-NMMA) but rose with subsequent L-arginine infusion. Acetylcholine caused an increase in flow velocity of 56±10% (range, 20% to 84%) compared with baseline (P<.01). Quantitative angiography showed no significant changes in artery diameter compared with control (L-NMMA, 98±1%; L-arginine, 99±2%; repeat control, 99+2%; P=NS). Discussion This study of children with normal pulmonary hemodynamics supports in vitro and animal data showing that resting pulmonary vascular tone is mediated in part by the release of NO.2-5 This is the first study in humans on the effects of inhibition of NO synthesis in the pulmonary circulation. NO is a potent vasodilator, and our observations suggest that its continuous release from pulmonary endothelium plays a major role in the maintenance of normal basal pulmonary vasorelaxation.
We investigated the role of endothelium in pulmonary vascular control in children by administering an inhibitor of EDRF synthesis (L-NMMA), the substrate for the synthetic pathway (L-arginine), and a pharmacological stimulator of EDRF production (acetylcholine). In this study, all were used as transient diagnostic tools rather than as anticipated therapeutic agents. Arterial diameter was unchanged during each of the infusions, indicating that the major effect of each agent was to alter vascular tone distal to the segmental pulmonary artery. The pattern of response was very similar in all the children studied. In each case, L-NMMA produced distal vasoconstriction in a dose-related manner, with the vasoactive 140 120 100 80 60.
effects occurring within 2 minutes. In experimental animal work, intrapulmonary administration of L-NMMA raises pulmonary artery pressure in the lamb.5 These data suggest that the normal pulmonary endothelium releases NO in the basal state, and the rapid inhibitory effect of L-NMMIA is consistent with the known short half-life of NO.
After L-NMMIA, L-arginine at the lower dose caused pulmonary flow velocity to return to control values within minutes, indicating that L-NMMA is a competitive antagonist of NO synthesis, which may be overcome by increasing substrate availability. Higher doses Of L-arginine, however, did not lead to further pulmonary vasorelaxation. Similar results have been reported in normal lambs; L-arginine had no pulmonary hemodynamic effects, even at high doses.'.' In the setting of pulmonary hypertension, however, in which endothelial function may be impaired, both L-arginine and NO may be important therapeutic agents, acting as pulmonary vasodilators. [15] [16] [17] In contrast to the response to L-arginine, acetylcholine did produce significant increases in pulmonary flow above baseline, suggesting that EDRF production can still be stimulated after L-arginine counteracts the effects of L-NMMA infusion. Acetylcholine has previously been shown to produce pulmonary vasorelaxation in normal subjects9'18 by pharmacological stimulation of endothelial cell muscarinic receptors.19 Although the precise mechanism whereby acetylcholine causes dilation of the resistance vessels is unknown, at least part of its effect is independent of NO.20.21
The physiological role of NO in the pulmonary circulation has been difficult to investigate until recently because of its labile nature, the lack of specific antagonists that could be safely reversed, and the lack of a method to study pulmonary endothelial function in vivo. In this study, we observed no systemic effects from giving L-NMMA, L-arginine, or acetylcholine into a small segment of one lung. The doses chosen were similar to those used by Vallance 
